Use of Viscoelastography in Malignancy-Associated Coagulopathy and Thrombosis: A Review

Abstract

The relationship between malignancy and coagulopathy is one that is well documented yet incompletely understood. Clinicians have attempted to quantify the hypercoagulable state produced in various malignancies using common coagulation tests such as prothrombin time, activated partial thromboplastin time, and platelet count; however, due to these tests' focus on individual aspects of coagulation during one specific time point, they have failed to provide clinicians the complete picture of malignancy-associated coagulopathy (MAC). Viscoelastic tests (VETs), such as thromboelastography (TEG) and rotational thromboelastometry (ROTEM), are whole blood analyses that have the advantage of providing information related to the cumulative effects of plasma clotting factors, platelets, leukocytes, and red cells during all stages of the coagulation and fibrinolytic processes. VETs have gained popularity in the care of trauma patients to objectively measure trauma-induced coagulopathy (TIC), but the utility of VETs remains yet unrealized in many other medical specialties. The authors discuss the similarities and differences between TIC and MAC, and propose a mechanism for the hypercoagulable state of MAC that revolves around the thrombomodulin–thrombin complex as it switches between activating the protein C anticoagulation pathway or the thrombin activatable fibrinolysis inhibitor coagulation pathway. Additionally, they review the current literature on the use of TEG and ROTEM in patients with various malignancies. Although limited research is currently available, early results demonstrate the utility of both TEG and ROTEM in the prediction of hypercoagulable states and thromboembolic complications in oncologic patients.

Keywords

coagulopathy - thromboembolism - ROTEM - TEG - malignancy - tumors - hypercoagulable

• References

• 1 Virchow RLK. Cellular Pathology: As Based upon Physiological and Pathological Histology. Twenty Lectures Delivered in the Pathological Institute of Berlin during the Months of February, March and April, 1858. New York, NY: RM De Witt; 1860
• 2 Bagot CN, Arya R. Virchow and his triad: a question of attribution. Br J Haematol 2008; 143 (02) 180-190
• 3 Kashuk JL, Moore EE, Sabel A. , et al. Rapid thrombelastography (r-TEG) identifies hypercoagulability and predicts thromboembolic events in surgical patients. Surgery 2009; 146 (04) 764-772 , discussion 772–774
• 4 Trousseau A. Clinique médicale de l'Hôtel-Dieu de Paris. Vol 2. Paris: Baillière; 1861
• 5 Sørensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343 (25) 1846-1850
• 6 Rickles FR, Edwards RL. Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood 1983; 62 (01) 14-31
• 7 Falanga A, Marchetti M, Vignoli A. Coagulation and cancer: biological and clinical aspects. J Thromb Haemost 2013; 11 (02) 223-233
• 8 Blom JW, Osanto S, Rosendaal FR. High risk of venous thrombosis in patients with pancreatic cancer: a cohort study of 202 patients. Eur J Cancer 2006; 42 (03) 410-414
• 9 Falanga A, Barbui T, Rickles FR, Levine MN. ; For the Scientific and Standardization Committee of the Subcommittee on Haemostasis and Malignancy International Society of Thrombosis and Haemostasis. Guidelines for clotting studies in cancer patients. Thromb Haemost 1993; 70 (03) 540-542
• 10 Falanga A, Schieppati F, Russo D. Cancer tissue procoagulant mechanisms and the hypercoagulable state of patients with cancer. Semin Thromb Hemost 2015; 41 (07) 756-764
• 11 Falanga A, Ofosu FA, Delaini F. , et al. The hypercoagulable state in cancer patients: evidence for impaired thrombin inhibitions. Blood Coagul Fibrinolysis 1994; 5 (01) , Suppl (Suppl. 01) S19-S23 , discussion 59–64
• 12 Lippi G, Salvagno GL, Ippolito L, Franchini M, Favaloro EJ. Shortened activated partial thromboplastin time: causes and management. Blood Coagul Fibrinolysis 2010; 21 (05) 459-463
• 13 Ay C, Dunkler D, Marosi C. , et al. Prediction of venous thromboembolism in cancer patients. Blood 2010; 116 (24) 5377-5382
• 14 Ay C, Vormittag R, Dunkler D. , et al. D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 2009; 27 (25) 4124-4129
• 15 Khorana AA, Francis CW, Culakova E, Lyman GH. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 2005; 104 (12) 2822-2829
• 16 Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111 (10) 4902-4907
• 17 Mandala M, Clerici M, Corradino I. , et al. Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the ‘SENDO experience’. Ann Oncol 2012; 23 (06) 1416-1421
• 18 Moore RA, Adel N, Riedel E. , et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol 2011; 29 (25) 3466-3473
• 19 Palumbo A, Rajkumar SV, Dimopoulos MA. , et al; International Myeloma Working Group. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008; 22 (02) 414-423
• 20 Verso M, Agnelli G, Barni S, Gasparini G, LaBianca R. A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern Emerg Med 2012; 7 (03) 291-292
• 21 Ay C, Simanek R, Vormittag R. , et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood 2008; 112 (07) 2703-2708
• 22 Lyman GH, Khorana AA, Falanga A. , et al; American Society of Clinical Oncology. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007; 25 (34) 5490-5505
• 23 Hincker A, Feit J, Sladen RN, Wagener G. Rotational thromboelastometry predicts thromboembolic complications after major non-cardiac surgery. Crit Care 2014; 18 (05) 549
• 24 Akay OM, Ustuner Z, Canturk Z, Mutlu FS, Gulbas Z. Laboratory investigation of hypercoagulability in cancer patients using rotation thrombelastography. Med Oncol 2009; 26 (03) 358-364
• 25 Levi M, Hunt BJ. A critical appraisal of point-of-care coagulation testing in critically ill patients. J Thromb Haemost 2015; 13 (11) 1960-1967
• 26 Ostrowski SR, Berg RM, Windeløv NA. , et al. Discrepant fibrinolytic response in plasma and whole blood during experimental endotoxemia in healthy volunteers. PLoS One 2013; 8 (03) e59368
• 27 Curry NS, Davenport R. Transfusion strategies for major haemorrhage in trauma. Br J Haematol 2019; 184 (04) 508-523
• 28 Walsh M, Jbara M, Miller A, Lawson J. Thromboelastographic goal-directed blood component therapy for severe hemorrhage. Blood Bulletin 2014 . Available at: http://www.cbccts.org/media/38370/BloodBulletin_March2014.pdf . Accessed April 10, 2019
• 29 Schöchl H, Maegele M, Solomon C, Görlinger K, Voelckel W. Early and individualized goal-directed therapy for trauma-induced coagulopathy. Scand J Trauma Resusc Emerg Med 2012; 20: 15
• 30 Meizoso JP, Karcutskie CA, Ray JJ, Namias N, Schulman CI, Proctor KG. Persistent fibrinolysis shutdown is associated with increased mortality in severely injured trauma patients. J Am Coll Surg 2017; 224 (04) 575-582
• 31 Moore EE, Moore HB, Gonzalez E. , et al. Postinjury fibrinolysis shutdown: rationale for selective tranexamic acid. J Trauma Acute Care Surg 2015; 78 (06) , Suppl (Suppl. 01) S65-S69
• 32 Valle EJ, Allen CJ, Van Haren RM. , et al. Do all trauma patients benefit from tranexamic acid?. J Trauma Acute Care Surg 2014; 76 (06) 1373-1378
• 33 Roberts DJ, Kalkwarf KJ, Moore HB. , et al. Time course and outcomes associated with transient versus persistent fibrinolytic phenotypes after injury: a nested, prospective, multicenter cohort study. J Trauma Acute Care Surg 2019; 86 (02) 206-213
• 34 Gary JL, Schneider PS, Galpin M. , et al. Can thrombelastography predict venous thromboembolic events in patients with severe extremity trauma?. J Orthop Trauma 2016; 30 (06) 294-298
• 35 Moore HB, Paniccia A, Lawson PJ. , et al. Utility of viscoelastic assays beyond coagulation: can preoperative thrombelastography indices predict tumor histology, nodal disease, and resectability in patients undergoing pancreatectomy?. J Am Coll Surg 2018; 227 (01) 55-62
• 36 Tun NM, Guevara E, Oo TH. Benefit and risk of primary thromboprophylaxis in ambulatory patients with advanced pancreatic cancer receiving chemotherapy: a systematic review and meta-analysis of randomized controlled trials. Blood Coagul Fibrinolysis 2016; 27 (03) 270-274
• 37 Toukh M, Siemens DR, Black A. , et al. Thromboelastography identifies hypercoagulablilty and predicts thromboembolic complications in patients with prostate cancer. Thromb Res 2014; 133 (01) 88-95
• 38 Hisada Y, Mackman N. Cancer-associated pathways and biomarkers of venous thrombosis. Blood 2017; 130 (13) 1499-1506
• 39 Pinto S, Gori L, Gallo O, Boccuzzi S, Paniccia R, Abbate R. Increased thromboxane A2 production at primary tumor site in metastasizing squamous cell carcinoma of the larynx. Prostaglandins Leukot Essent Fatty Acids 1993; 49 (01) 527-530
• 40 Boccaccio C, Sabatino G, Medico E. , et al. The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature 2005; 434 (7031): 396-400
• 41 Varki A. Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood 2007; 110 (06) 1723-1729
• 42 Nickel KF, Ronquist G, Langer F. , et al. The polyphosphate-factor XII pathway drives coagulation in prostate cancer-associated thrombosis. Blood 2015; 126 (11) 1379-1389
• 43 Zucchella M, Dezza L, Pacchiarini L. , et al. Human tumor cells cultured “in vitro” activate platelet function by producing ADP or thrombin. Haematologica 1989; 74 (06) 541-545
• 44 Shao B, Wahrenbrock MG, Yao L. , et al. Carcinoma mucins trigger reciprocal activation of platelets and neutrophils in a murine model of Trousseau syndrome. Blood 2011; 118 (15) 4015-4023
• 45 Giaccherini C, Verzeroli C, Marchetti M. , et al. PO-26 - Whole blood rotational thromboelastometry (ROTEM) to detect hypercoagulability in patients with myeloproliferative neoplasms (MPN). Thromb Res 2016; 140 (Suppl. 01) S185-S186
• 46 Kessler CM. Propensity for hemorrhage and thrombosis in chronic myeloproliferative disorders. Semin Hematol 2004; 41 (02) (Suppl. 03) 10-14
• 47 Honegger H, Anderson N, Hewitt LA, Tullis JL. Antithrombin III profiles in malignancy, relationship primary tumors and metastatic sites. Thromb Haemost 1981; 46 (02) 500-503
• 48 Ponticelli C. Membranous nephropathy. J Nephrol 2007; 20 (03) 268-287
• 49 Dobson GP, Letson HL, Sharma R, Sheppard FR, Cap AP. Mechanisms of early trauma-induced coagulopathy: the clot thickens or not?. J Trauma Acute Care Surg 2015; 79 (02) 301-309
• 50 Johansson PI, Stensballe J, Ostrowski SR. Shock induced endotheliopathy (SHINE) in acute critical illness - a unifying pathophysiologic mechanism. Crit Care 2017; 21 (01) 25
• 51 Brohi K, Cohen MJ, Ganter MT, Matthay MA, Mackersie RC, Pittet JF. Acute traumatic coagulopathy: initiated by hypoperfusion: modulated through the protein C pathway?. Ann Surg 2007; 245 (05) 812-818
• 52 Díez N, Montes R, Alonso A. , et al. Association of increased fibrinogen concentration with impaired activation of anticoagulant protein C. J Thromb Haemost 2006; 4 (02) 398-402
• 53 Kwaan HC, Cull EH. The coagulopathy in acute promyelocytic leukaemia--what have we learned in the past twenty years. Best Pract Res Clin Haematol 2014; 27 (01) 11-18
• 54 Kwaan HC, Rego EM. Role of microparticles in the hemostatic dysfunction in acute promyelocytic leukemia. Semin Thromb Hemost 2010; 36 (08) 917-924
• 55 Liu Y, Wang Z, Jiang M. , et al. The expression of annexin II and its role in the fibrinolytic activity in acute promyelocytic leukemia. Leuk Res 2011; 35 (07) 879-884
• 56 Stein E, McMahon B, Kwaan H, Altman JK, Frankfurt O, Tallman MS. The coagulopathy of acute promyelocytic leukaemia revisited. Best Pract Res Clin Haematol 2009; 22 (01) 153-163
• 57 Tallman MS, Kwaan HC. Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood 1992; 79 (03) 543-553
• 58 Zakarija A, Kwaan HC. Adverse effects on hemostatic function of drugs used in hematologic malignancies. Semin Thromb Hemost 2007; 33 (04) 355-364
• 59 Kwaan HC, Rego EM, McMahon B, Weiss I, Marvin J. Microparticles in acute promyelocytic leukemia. Blood 2011; 118 (21) 3346
• 60 Mutch NJ, Engel R, Uitte de Willige S, Philippou H, Ariëns RAJB. Polyphosphate modifies the fibrin network and down-regulates fibrinolysis by attenuating binding of tPA and plasminogen to fibrin. Blood 2010; 115 (19) 3980-3988
• 61 Esmon CT. Molecular circuits in thrombosis and inflammation. Thromb Haemost 2013; 109 (03) 416-420
• 62 Hardaway R, Bredenberg C. Monitoring hematology laboratory values. In: Care of Wounded in Vietnam. Manhattan, KS: Sunflower University Press; 1988: 139-220
• 63 Hartert H, Schaeder J. The physical and biological constants of thrombelastography. Biorheology 1962; 1 (01) 31-39
• 64 Kang YG, Martin DJ, Marquez J. , et al. Intraoperative changes in blood coagulation and thrombelastographic monitoring in liver transplantation. Anesth Analg 1985; 64 (09) 888-896
• 65 Enriquez LJ, Shore-Lesserson L. Point-of-care coagulation testing and transfusion algorithms. Br J Anaesth 2009; 103 (01) , Suppl (Suppl. 01) i14-i22
• 66 Shore-Lesserson L, Manspeizer HE, DePerio M, Francis S, Vela-Cantos F, Ergin MA. Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery. Anesth Analg 1999; 88 (02) 312-319
• 67 Johansson PI, Stissing T, Bochsen L, Ostrowski SR. Thrombelastography and tromboelastometry in assessing coagulopathy in trauma. Scand J Trauma Resusc Emerg Med 2009; 17 (01) 45
• 68 Kaufmann CR, Dwyer KM, Crews JD, Dols SJ, Trask AL. Usefulness of thrombelastography in assessment of trauma patient coagulation. J Trauma 1997; 42 (04) 716-720 , discussion 720–722
• 69 Spiel AO, Mayr FB, Firbas C, Quehenberger P, Jilma B. Validation of rotation thrombelastography in a model of systemic activation of fibrinolysis and coagulation in humans. J Thromb Haemost 2006; 4 (02) 411-416
• 70 Traverso CI, Caprini JA, Arcelus JI. The normal thromboelastogram and its interpretation. Semin Thromb Hemost 1995; 21 (Suppl (Suppl. 04) 7-13
• 71 Walsh M, Fritz S, Hake D. , et al. Targeted thromboelastographic (TEG) blood component and pharmacologic hemostatic therapy in traumatic and acquired coagulopathy. Curr Drug Targets 2016; 17 (08) 954-970
• 72 Gorlinger K, Bhardwaj V, Kapoor PM. Simulation in coagulation testing using rotational thromboelastometry: a fast emerging, reliable point of care technique. Ann Card Anaesth 2016; 19 (03) 516-520
• 73 Johansson PI. Coagulation monitoring of the bleeding traumatized patient. Curr Opin Anaesthesiol 2012; 25 (02) 235-241
• 74 Gonzalez E, Pieracci FM, Moore EE, Kashuk JL. Coagulation abnormalities in the trauma patient: the role of point-of-care thromboelastography. Semin Thromb Hemost 2010; 36 (07) 723-737
• 75 Moore HB, Moore EE, Gonzalez E. , et al. Hyperfibrinolysis, physiologic fibrinolysis, and fibrinolysis shutdown: the spectrum of postinjury fibrinolysis and relevance to antifibrinolytic therapy. J Trauma Acute Care Surg 2014; 77 (06) 811-817 , discussion 817
• 76 Görlinger K, Fries D, Dirkmann D, Weber CF, Hanke AA, Schöchl H. Reduction of fresh frozen plasma requirements by perioperative point-of-care coagulation management with early calculated goal-directed therapy. Transfus Med Hemother 2012; 39 (02) 104-113
• 77 Goldenberg NA, Hathaway WE, Jacobson L, Manco-Johnson MJ. A new global assay of coagulation and fibrinolysis. Thromb Res 2005; 116 (04) 345-356
• 78 Holcomb JB, Minei KM, Scerbo ML. , et al. Admission rapid thrombelastography can replace conventional coagulation tests in the emergency department: experience with 1974 consecutive trauma patients. Ann Surg 2012; 256 (03) 476-486
• 79 Davenport R, Manson J, De'Ath H. , et al. Functional definition and characterization of acute traumatic coagulopathy. Crit Care Med 2011; 39 (12) 2652-2658
• 80 Kitchens CS. To bleed or not to bleed? Is that the question for the PTT?. J Thromb Haemost 2005; 3 (12) 2607-2611
• 81 Segal JB, Dzik WH. ; Transfusion Medicine/Hemostasis Clinical Trials Network. Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: an evidence-based review. Transfusion 2005; 45 (09) 1413-1425
• 82 Toulon P, Ozier Y, Ankri A, Fléron M-H, Leroux G, Samama CM. Point-of-care versus central laboratory coagulation testing during haemorrhagic surgery. A multicenter study. Thromb Haemost 2009; 101 (02) 394-401
• 83 Schöchl H, Solomon C, Voelckel W. Thromboelastometry in the perioperative setting. Neth J Crit Care 2010; 14 (01) 23-31
• 84 Scărlătescu E, Lancé MD, White NJ, Aramă SS, Tomescu DR. Effects of malignancy on blood coagulation in septic intensive care patients. Blood Coagul Fibrinolysis 2018; 29 (01) 92-96
• 85 Ostrowski SR, Windeløv NA, Ibsen M, Haase N, Perner A, Johansson PI. Consecutive thrombelastography clot strength profiles in patients with severe sepsis and their association with 28-day mortality: a prospective study. J Crit Care 2013; 28 (03) 317.e1-317.e11
• 86 Kander T, Larsson A, Taune V, Schött U, Tynngård N. Assessment of haemostasis in disseminated intravascular coagulation by use of point-of-care assays and routine coagulation tests, in critically ill patients; a prospective observational study. PLoS One 2016; 11 (03) e0151202
• 87 Park MS, Martini WZ, Dubick MA. , et al. Thromboelastography as a better indicator of hypercoagulable state after injury than prothrombin time or activated partial thromboplastin time. J Trauma 2009; 67 (02) 266-276
• 88 Liang H, Yang CX, Li H, Wen XJ, Zhou QL, Gu MN. The effects of preloading infusion with hydroxyethyl starch 200/0.5 or 130/0.4 solution on hypercoagulability and excessive platelet activation of patients with colon cancer. Blood Coagul Fibrinolysis 2010; 21 (05) 406-413
• 89 Wang Z-W, Ye P-J. Clinical analysis of acute cerebral infarction accompanied with lung cancer. J Acute Dis 2016; 5 (04) 307-310
• 90 Thorson CM, Van Haren RM, Ryan ML. , et al. Persistence of hypercoagulable state after resection of intra-abdominal malignancies. J Am Coll Surg 2013; 216 (04) 580-589 , discussion 589–590
• 91 Thorson CM, Van Haren RM, Ryan ML. , et al. Pre-existing hypercoagulability in patients undergoing potentially curative cancer resection. Surgery 2014; 155 (01) 134-144
• 92 Bagatin D, Šakić K, Bagatin T, Šturm D, Milošević M. Does rotation thrombelastometry (ROTEM) improve early prediction of coagulopathy in breast tumor?. Period Biol 2015; 117 (02) 291-296
• 93 Cohen E, Caprini J, Zuckerman L, Vagher P, Robinson B. Evaluation of three methods used to identify accelerated coagulability. Thromb Res 1977; 10 (04) 587-604
• 94 Levi M. Diagnosis and treatment of disseminated intravascular coagulation. Int J Lab Hematol 2014; 36 (03) 228-236
• 95 Asakura H, Takahashi H, Uchiyama T. , et al; DIC subcommittee of the Japanese Society on Thrombosis and Hemostasis. Proposal for new diagnostic criteria for DIC from the Japanese Society on Thrombosis and Hemostasis. Thromb J 2016; 14 (01) 42
• 96 Brenner T, Schmidt K, Delang M. , et al. Viscoelastic and aggregometric point-of-care testing in patients with septic shock - cross-links between inflammation and haemostasis. Acta Anaesthesiol Scand 2012; 56 (10) 1277-1290
• 97 Collins PW, Macchiavello LI, Lewis SJ. , et al. Global tests of haemostasis in critically ill patients with severe sepsis syndrome compared to controls. Br J Haematol 2006; 135 (02) 220-227
• 98 Daudel F, Kessler U, Folly H, Lienert JS, Takala J, Jakob SM. Thromboelastometry for the assessment of coagulation abnormalities in early and established adult sepsis: a prospective cohort study. Crit Care 2009; 13 (02) R42
• 99 Dempfle C-E, Borggrefe M. Point of care coagulation tests in critically ill patients. Semin Thromb Hemost 2008; 34 (05) 445-450
• 100 Johansson PI, Stensballe J, Vindeløv N, Perner A, Espersen K. Hypocoagulability, as evaluated by thrombelastography, at admission to the ICU is associated with increased 30-day mortality. Blood Coagul Fibrinolysis 2010; 21 (02) 168-174
• 101 Müller MC, Meijers JC, Vroom MB, Juffermans NP. Utility of thromboelastography and/or thromboelastometry in adults with sepsis: a systematic review. Crit Care 2014; 18 (01) R30
• 102 Meizoso JP, Ray JJ, Allen CJ. , et al. Hypercoagulability and venous thromboembolism in burn patients. Semin Thromb Hemost 2015; 41 (01) 43-48
• 103 Starzl TE. The saga of liver replacement, with particular reference to the reciprocal influence of liver and kidney transplantation (1955-1967). J Am Coll Surg 2002; 195 (05) 587-610
• 104 Groth CG, Pechet L, Starzl TE. Coagulation during and after orthotopic transplantation of the human liver. Arch Surg 1969; 98 (01) 31-34
• 105 Stravitz RT. Potential applications of thromboelastography in patients with acute and chronic liver disease. Gastroenterol Hepatol (N Y) 2012; 8 (08) 513-520
• 106 Fergusson DA, Hébert PC, Mazer CD. , et al; BART Investigators. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 2008; 358 (22) 2319-2331
• 107 Agarwal B, Wright G, Gatt A. , et al. Evaluation of coagulation abnormalities in acute liver failure. J Hepatol 2012; 57 (04) 780-786
• 108 Mallett SV. Clinical utility of viscoelastic tests of coagulation (TEG/ROTEM) in patients with liver disease and during liver transplantation. Semin Thromb Hemost 2015; 41 (05) 527-537
• 109 Stravitz RT, Lisman T, Luketic VA. , et al. Minimal effects of acute liver injury/acute liver failure on hemostasis as assessed by thromboelastography. J Hepatol 2012; 56 (01) 129-136
• 110 Myers SP, Kutcher ME, Rosengart MR. , et al. Tranexamic acid administration is associated with an increased risk of posttraumatic venous thromboembolism. J Trauma Acute Care Surg 2019; 86 (01) 20-27
• 111 Harvin JA, Peirce CA, Mims MM. , et al. The impact of tranexamic acid on mortality in injured patients with hyperfibrinolysis. J Trauma Acute Care Surg 2015; 78 (05) 905-909 , discussion 909–911
• 112 Moore HB, Moore EE, Liras IN. , et al. Acute fibrinolysis shutdown after injury occurs frequently and increases mortality: a multicenter evaluation of 2,540 severely injured patients. J Am Coll Surg 2016; 222 (04) 347-355
• 113 Sawaya R, Ramo OJ, Glas-Greenwalt P, Wu SZ. Plasma fibrinolytic profile in patients with brain tumors. Thromb Haemost 1991; 65 (01) 15-19
• 114 Chapman MP, Moore EE, Moore HB. , et al. Overwhelming tPA release, not PAI-1 degradation, is responsible for hyperfibrinolysis in severely injured trauma patients. J Trauma Acute Care Surg 2016; 80 (01) 16-23 , discussion 23–25
• 115 Moore HB, Moore EE, Lawson PJ. , et al. Fibrinolysis shutdown phenotype masks changes in rodent coagulation in tissue injury versus hemorrhagic shock. Surgery 2015; 158 (02) 386-392
• 116 Prat NJ, Montgomery R, Cap AP. , et al. Comprehensive evaluation of coagulation in swine subjected to isolated primary blast injury. Shock 2015; 43 (06) 598-603
• 117 Butler MJ. Thrombelastography during and after elective abdominal surgery. Thromb Haemost 1978; 39 (02) 488-495
• 118 Goh KY-C, Tsoi W-C, Feng C-S, Wickham N, Poon WS. Haemostatic changes during surgery for primary brain tumours. J Neurol Neurosurg Psychiatry 1997; 63 (03) 334-338
• 119 Howland WS, Castro EB, Fortner JB, Gould P. Proceedings: hypercoagulability. Thrombelastographic monitoring during extensive hepatic surgery. Arch Surg 1974; 108 (04) 605-608
• 120 Mahla E, Lang T, Vicenzi MN. , et al. Thromboelastography for monitoring prolonged hypercoagulability after major abdominal surgery. Anesth Analg 2001; 92 (03) 572-577
• 121 Artang R, Jensen E, Pedersen F, Frandsen NJ. Thrombelastography in healthy volunteers, patients with stable angina and acute chest pain. Thromb Res 2000; 97 (06) 499-503
• 122 Holloway DS, Vagher JP, Caprini JA, Simon NM, Mockros LF. Thrombelastography of blood from subjects with chronic renal failure. Thromb Res 1987; 45 (06) 817-825
• 123 Fisch IR, Freedman SH. Oral contraceptives, ABO blood groups, and in vitro fibrin formation. Obstet Gynecol 1975; 46 (04) 473-479
• 124 Spillert CR, McGovern PJ, Vidaver RM, Lazaro EJ. Thromboelastographic evaluation of cut down-induced accelerated coagulation. Thromb Haemost 1981; 46 (02) 567-567
• 125 Blasi A, Molina V, Sanchez-Cabús S, Balust J, Garcia-Valdecasas JC, Taura P. Prediction of thromboembolic complications after liver resection for cholangiocarcinoma: is there a place for thromboelastometry?. Blood Coagul Fibrinolysis 2018; 29 (01) 61-66
• 126 De Pietri L, Montalti R, Begliomini B. , et al. Thromboelastographic changes in liver and pancreatic cancer surgery: hypercoagulability, hypocoagulability or normocoagulability?. Eur J Anaesthesiol 2010; 27 (07) 608-616
• 127 Papa ML, Capasso F, Pudore L. , et al. Thromboelastographic profiles as a tool for thrombotic risk in digestive tract cancer. Exp Oncol 2007; 29 (02) 111-115
• 128 Francis JL, Francis DA, Gunathilagan GJ. Assessment of hypercoagulability in patients with cancer using the Sonoclot Analyzer and thromboelastography. Thromb Res 1994; 74 (04) 335-346
• 129 Wikner J, Beck-Broichsitter BE, Schlesinger S. , et al. Thromboelastometry: a contribution to perioperative free-flap management. J Craniomaxillofac Surg 2015; 43 (07) 1065-1071
• 130 Wen YR, Ho WY, Sun WZ. , et al. Thromboelastographic study of thrombosis in the implantable central venous access device. Acta Anaesthesiol Sin 1997; 35 (04) 223-228
• 131 Attaran S, Somov P, Awad WI. Randomised high- and low-dose heparin prophylaxis in patients undergoing thoracotomy for benign and malignant disease: effect on thrombo-elastography. Eur J Cardiothorac Surg 2010; 37 (06) 1384-1390
• 132 Akay MO, Bilir A, Öge T, Kuş G, Mutlu FŞ. The evaluation of hydroxyethyl starch (6% HES 130/0.4) solution's potential preventive effects on coagulation status in women with gynecologic malignancies using rotation thromboelastography. Turk J Haematol 2014; 31 (03) 261-265
• 133 Jansohn E, Bengzon J, Kander T, Schött U. A pilot study on the applicability of thromboelastometry in detecting brain tumour-induced hypercoagulation. Scand J Clin Lab Invest 2017; 77 (04) 289-294
• 134 Kwaan HC, Wang J, Boggio LN. Abnormalities in hemostasis in acute promyelocytic leukemia. Hematol Oncol 2002; 20 (01) 33-41
• 135 Gracheva MA, Urnova ES, Sinauridze EI. , et al. Thromboelastography, thrombin generation test and thrombodynamics reveal hypercoagulability in patients with multiple myeloma. Leuk Lymphoma 2015; 56 (12) 3418-3425
• 136 Ko RH, Sposto R, Goodarzian F, Carmona R, Vasquez S, Young G. Thromboelastography to detect hypercoagulability in patients with newly diagnosed acute lymphoblastic leukemia. Blood 2015; 126 (23) 1118
• 137 Crowley MP, Quinn S, Coleman ET, O'Shea SI, Gilligan OM. The evolving hemostatic profile of patients with myeloma receiving treatment. Comp Clin Pathol 2017; 26 (03) 713-717
• 138 Crowley MP, Quinn S, Coleman E, Eustace JA, Gilligan OM, O'Shea SI. Differing coagulation profiles of patients with monoclonal gammopathy of undetermined significance and multiple myeloma. J Thromb Thrombolysis 2015; 39 (02) 245-249
• 139 Flisberg P, Rundgren M, Engström M. The effects of platelet transfusions evaluated using rotational thromboelastometry. Anesth Analg 2009; 108 (05) 1430-1432
• 140 Akay OM, Goren Sahin D, Andic N. , et al. The utility of thromboelastometry in prophylactic platelet transfusion for hematological malignancies. Transfus Apheresis Sci 2015; 53 (01) 64-68
• 141 Sur S, Sugimoto JT, Agrawal DK. Coronary artery bypass graft: why is the saphenous vein prone to intimal hyperplasia?. Can J Physiol Pharmacol 2014; 92 (07) 531-545
• 142 Cardenas JC, Wade CE, Cotton BA. , et al. TEG lysis shutdown represents coagulopathy in bleeding trauma patients: analysis of the proppr cohort. Shock 2019; 51 (03) 273-283
• 143 Gall LS, Davenport RA. Fibrinolysis and antifibrinolytic treatment in the trauma patient. Curr Opin Anaesthesiol 2018; 31 (02) 227-233
• 144 Gall LS, Vulliamy P, Gillespie S. , et al. The S100A10 pathway mediates an occult hyperfibrinolytic subtype in trauma patients. Ann Surg 2018 (e-pub ahead of print). doi:10.1097/SLA.0000000000002733
• 145 Hunt H, Stanworth S, Curry N. , et al. Thromboelastography (TEG) and rotational thromboelastometry (ROTEM) for trauma induced coagulopathy in adult trauma patients with bleeding. Cochrane Database Syst Rev 2015; (02) CD010438
• 146 Wikkelsø A, Wetterslev J, Møller AM, Afshari A. Thromboelastography (TEG) or rotational thromboelastometry (ROTEM) to monitor haemostatic treatment in bleeding patients: a systematic review with meta-analysis and trial sequential analysis. Anaesthesia 2017; 72 (04) 519-531
• 147 Wikkelsø A, Wetterslev J, Møller AM, Afshari A. Thromboelastography (TEG) or thromboelastometry (ROTEM) to monitor haemostatic treatment versus usual care in adults or children with bleeding. Cochrane Database Syst Rev 2016; (08) CD007871
• 148 Galster H, Kolb G, Kohsytorz A, Seidlmayer C, Paal V. The pre-, peri-, and postsurgical activation of coagulation and the thromboembolic risk for different risk groups. Thromb Res 2000; 100 (05) 381-388
• 149 Garcia-Avello A, Galindo-Alvarez J, Martinez-Molina E, Cesar-Perez J, Navarro JL. Coagulative system activation and fibrinolytic system inhibition activities arise from tumoral draining vein in colon carcinoma. Thromb Res 2001; 104 (06) 421-425
• 150 Gall L, Davenport R, Brohi K. Effect of early tranexamic acid on the coagulation system in patients with suspected traumatic haemorrhage: a prospective cohort study. Lancet 2016; 387: S46
• 151 Raza I, Davenport R, Rourke C. , et al. The incidence and magnitude of fibrinolytic activation in trauma patients. J Thromb Haemost 2013; 11 (02) 307-314
• 152 Gomez-Builes JC, Acuna SA, Nascimento B, Madotto F, Rizoli SBJA. Harmful or physiologic: diagnosing fibrinolysis shutdown in a trauma cohort with rotational thromboelastometry. Anesth Analg 2018; 127 (04) 840-849
• 153 Zufferey PJ, Miquet M, Quenet S. , et al; Tranexamic acid in hip-fracture surgery (THIF) study. Tranexamic acid in hip fracture surgery: a randomized controlled trial. Br J Anaesth 2010; 104 (01) 23-30
• 154 Kassis J, Hirsh J, Podor TJ. Evidence that postoperative fibrinolytic shutdown is mediated by plasma factors that stimulate endothelial cell type I plasminogen activator inhibitor biosynthesis. Blood 1992; 80 (07) 1758-1764
• 155 Yukizawa Y, Inaba Y, Watanabe S. , et al. Association between venous thromboembolism and plasma levels of both soluble fibrin and plasminogen-activator inhibitor 1 in 170 patients undergoing total hip arthroplasty. Acta Orthop 2012; 83 (01) 14-21
• 156 Kleiss SF, Adelmeijer J, Meijers JCM, Porte RJ, Lisman T. A sustained decrease in plasma fibrinolytic potential following partial liver resection or pancreas resection. Thromb Res 2016; 140: 36-40
• 157 Roberts I, Shakur H, Coats T. , et al. The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients. Health Technol Assess 2013; 17 (10) 1-79
• 158 Letson HL, Dobson GP. Tranexamic acid for post-partum haemorrhage in the WOMAN trial. Lancet 2017; 390 (10102): 1581-1582
• 159 The CRASH trial management group; The CRASH trial collaborators. The CRASH trial protocol (Corticosteroid randomisation after significant head injury) [ISRCTN74459797]. BMC Emerg Med 2001; 1 (01) 1-10
• 160 Shakur H, Elbourne D, Gülmezoglu M. , et al. The WOMAN Trial (World Maternal Antifibrinolytic Trial): tranexamic acid for the treatment of postpartum haemorrhage: an international randomised, double blind placebo controlled trial. Trials 2010; 11 (01) 40
• 161 Walsh M, Thomas S, Moore E. , et al. Tranexamic acid for trauma resuscitation in the United States of America. Semin Thromb Hemost 2017; 43 (02) 213-223
• 162 Henriquez DDCA, Bloemenkamp KWM, van der Bom JG. Management of postpartum hemorrhage: how to improve maternal outcomes?. J Thromb Haemost 2018; 8: 1523-1534
• 163 Sentilhes L, Winer N, Azria E. , et al; Groupe de Recherche en Obstétrique et Gynécologie. Tranexamic acid for the prevention of blood loss after vaginal delivery. N Engl J Med 2018; 379 (08) 731-742
• 164 Tignanelli CJ, Napolitano LM. The fragility index in randomized clinical trials as a means of optimizing patient care. JAMA Surg 2018; 154: 74-79
• 165 Beckmann JS, Lew D. Reconciling evidence-based medicine and precision medicine in the era of big data: challenges and opportunities. Genome Med 2016; 8 (01) 134
• 166 Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med 2015; 372 (09) 793-795
• 167 Moore HB, Moore EE, Morton AP. , et al. Shock-induced systemic hyperfibrinolysis is attenuated by plasma-first resuscitation. J Trauma Acute Care Surg 2015; 79 (06) 897-903 , discussion 903–904
• 168 Hildyard C, Curry N. Point-of-care testing: a standard of care?. Anaesthesia 2015; 70 (10) 1113-1118
• 169 Korpallová B, Samoš M, Bolek T. , et al. Role of thromboelastography and rotational thromboelastometry in the management of cardiovascular diseases. Clin Appl Thromb Hemost 2018; 24 (08) 1199-1207
• 170 Duffield C, Davies R, Barclay P. Advances in thromboelastograph technology. Anaesthesia 2018; 73 (03) 398-399
• 171 Hans GA, Besser MW. The place of viscoelastic testing in clinical practice. Br J Haematol 2016; 173 (01) 37-48
• 172 Walsh M, Shreve J, Thomas S. , et al. Fibrinolysis in trauma: “myth,” “reality,” or “something in between”. Semin Thromb Hemost 2017; 43 (02) 200-212
• 173 Li R, Elmongy H, Sims C, Diamond SL. Ex vivo recapitulation of trauma-induced coagulopathy and preliminary assessment of trauma patient platelet function under flow using microfluidic technology. J Trauma Acute Care Surg 2016; 80 (03) 440-449
• 174 Kim D, Wu X, Young AT, Haynes CL. Microfluidics-based in vivo mimetic systems for the study of cellular biology. Acc Chem Res 2014; 47 (04) 1165-1173
• 175 Raskob GE, van Es N, Verhamme P. , et al; Hokusai VTE Cancer Investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018; 378 (07) 615-624
• 176 Gottlieb A, Mraovic B, Sprung J, Potter P, Kottke-Marchant K. The usefulness of thromboelastography in determining the coagulation effects of low-molecular-weight heparin. Anesth Analg 1999; 88 (2S): 274S
• 177 Zmuda K, Neofotistos D, Ts'ao CH. Effects of unfractionated heparin, low-molecular-weight heparin, and heparinoid on thromboelastographic assay of blood coagulation. Am J Clin Pathol 2000; 113 (05) 725-731